Dr Reddy's achieves major milestone with generic Semaglutide launch in Canada. The Hyderabad-based pharmaceutical company received Health Canada approval on April 28, 2026, making Canada the first G7 nation to authorize the generic injection. The drug treats type 2 diabetes and is available in pre-filled pens at 2mg and 4mg strengths. CEO Erez Israeli emphasized the company's commitment to delivering affordable GLP-1 therapies globally. This launch follows Dr Reddy's recent India introduction under the brand Obeda and demonstrates the company's expertise in complex peptide development. The competitive pricing strategy aims to improve patient access across multiple markets as GLP-1 therapies gain prominence in diabetes treatment worldwide.
